Focal HIFU in treatment of (largely) intermediate-risk prostate cancer

In addition to the French data previously referred to on this site, data from another, much larger cohort of men treated with focal, high-intensity focused ultrasound (focal HIFU) are also to be presented at the upcoming annual meeting of the American Urological Association.

HIFU for hemiablation of localized prostate cancer

A major plenary presentation at the upcoming annual meeting of the American Urological Association (AUA) will provide data from a rather small French trial of  high-intensity focused ultrasound (HIFU) in the focal management of localized prostate cancer.

5-year outcomes from a large cohort of HIFU-treated patients in the UK

For several years now, the Ahmed/Emberton-led research team in the United Kingdom (UK) has published the majority of the detailed outcomes data from treatment of men with localized prostate cancer using high-intensity focused ultrasound (HIFU). This group has now given us 5-year outcomes on a cohort of > 550 patients.

PBRT as a form of salvage radiation therapy after cryotherapy and HIFU

A new paper in “the Red Journal” prvides some information about the potential of proton beam radiation therapy (PBRT) as a salvage therapy in men who have failed either cryotherapy or first-line high-intensity focused ultrasound (HIFU) as first-line therapy for localized prostate cancer.

Data from a prospective trial of HIFU-based hemiablation for localized prostate cancer

A new report provides data from a prospective, single-center, Phase II trial of high-intensity focused ultrasound (HIFU) in prostate cancer hemiablation as a form of focal therapy. The study was carried out in Belgium.

The FDA’s perspective on the approval of HIFU in the USA

For those able to access the February 2016 issue of the AUA News, it carries an interesting article outlining the U.S. Food and Drug Administration’s perspective on exactly why the agency decided to approve two forms of high-intensity focused ultrasound (HIFU) technology for the transrectal ablation of prostate tissue.

FDA approves EDAP TMS’s Ablatherm technology for HIFU therapy

As predicted, the U.S. Food and Drug Administration apparently approved the Ablatherm brand of equipment for high-intensity focused ultrasound (HIFU) on November 9 for “the ablation of prostate tissue.”

Focal HIFU is “sexual function sparing” in a cohort of 118 selected patients

A new paper in European Urology has suggested that men with localized prostate cancer who are treated by focal forms of high-intensity focused ultrasound (HIFU) have “a return to baseline International Index of Erectile Function — erectile and total International Index of Erectile Function scores” by 6 months after treatment which was maintained at 1 […]

CureTalk about HIFU for prostate cancer now available on line

Your sitemaster is pleased to be able to report a forthright and interesting discussion yesterday with Dr. Stephen Scionti about the current and future potential of high-intensity focused ultrasound (HIFU) in the treatment of prostate cancer.

Our next prostate cancer CureTalk — with Dr. Stephen Scionti about the role of HIFU

Dr. Stephen Scionti is almost certainly the most experienced practitioner of high-intensity focused ultrasound (HIFU) as a first-line treatment for prostate cancer practicing in the USA today — although he has had to actually treat the vast majority of his patients outside of the USA.

EDAP TMS submits revised application for approval of their form of HIFU technology

As predicted in yesterday’s post about the nature of the approval of SonaCare Medical’s Sonablate technology as a “generic” form of treatment for prostate tissue ablation, we are likely to see rapid approval of the Ablatherm brand of HIFU technology here in America very soon as well.

Approval criteria for SonaCare Medical’s HIFU technology

The U.S. Food & Drug Administration has now posted, on its web site, the approval letter issued to SonaCare Medical with reference to the approval to market the company’s Sonablate® 450 technology.

FDA approves HIFU for “prostate tissue ablation”

According to a media release issued by SonaCare Medical early this morning, the company has received approval from the U.S. Food and Drug Administration (FDA) to market its Sonablate® 450 technology in the U.S.A. for prostate tissue ablation.

Approval of some form of Sonacare Medical’s HIFU technology?

Readers may wish to be aware that your sitemaster has been hearing whispers and rumblings that the U.S. Food and Drug Administration is either about to or has just approved some form of Sonacare Medical’s Sonablate high-intensity focal ultrasound (HIFU) techology for treatment of something related to the prostate.

Similar long-term outcomes after treatment with HIFU or LDR brachytherapy

The chances that we will ever see a large, randomized, comparative trial of high-intensity focused ultrasound (HIFU) and low-dose-rate (LDR) brachytherapy in the treatment of localized prostate cancer are near to zero.

Follow

Get every new post delivered to your Inbox.

Join 1,450 other followers